October 14, 2024: The UK's leading life sciences sector is set to receive a £279 million boost to address major health challenges, as Lilly, the world's largest pharmaceutical company, has expressed its intent to invest in the UK.
Under a new collaboration outlined in a memorandum of understanding, Lilly will support the UK’s top life sciences talent through the launch of the first 'Lilly Gateway Labs' innovation accelerator in Europe. This facility aims to assist early-stage life sciences companies in developing transformative medicines by providing lab space, mentorship, and potential financial support to drive future growth in the sector.
Obesity, recognised as the second leading preventable cause of cancer, significantly contributes to health issues that hinder individuals from fully participating in the workforce. This partnership aims to combine treatments and technologies from the life sciences sector with the healthcare system to show improved long-term health outcomes for those affected by obesity.
In a government press release, NHS chief executive Amanda Pritchard said, “Obesity is one of the biggest public health issues we face, and we know weight loss drugs will be a game-changer, alongside earlier prevention strategies, in supporting many more people to lose weight and reduce their risk of killer conditions like diabetes, heart attack and stroke. Today’s momentous agreement shows the NHS is uniquely well-placed globally, not just to bring effective new treatments to those who would benefit most, but also to support science, research, jobs and economic growth across the country. We now have an important chance to gain a better understanding of the benefits of weight management interventions for patients, and how best to deliver them over the next few years.”
The collaboration with Lilly aims to facilitate trials of innovative approaches to treating obesity, as part of a comprehensive care package. With obesity costing the UK health service over £11 billion annually, immediate action is essential. Supporting the life sciences sector to further understand obesity, along with implementing preventive measures such as restrictions on junk food advertising, will help alleviate pressure on the NHS.
The Government’s primary mission is to drive economic growth and enhance the lives of hardworking British citizens. The life sciences sector, which attracted £800 million in foreign direct investment to the UK in 2023, plays a crucial role in these efforts.
David A. Ricks, Chair and CEO of Eli Lilly & Company added, “We welcome this opportunity to partner with the UK Government on tackling and preventing disease, and accelerating innovation to advance care delivery models. Today’s announcement is an important milestone, and we are pleased to reinforce Lilly’s commitment to improving health for people living with obesity and its serious consequences.”
With a significant investment to foster innovation and support early-stage life sciences companies, this initiative aims to relieve pressure on the NHS and underscores the ongoing commitment to enhancing public health and driving economic growth across the UK.
